Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2006;48:213-218
Published online before print June 19, 2006, doi: 10.1161/01.HYP.0000229653.73128.b6
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
48/2/213    most recent
01.HYP.0000229653.73128.b6v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stafford, R. S.
Right arrow Articles by Ma, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stafford, R. S.
Right arrow Articles by Ma, J.
Related Collections
Right arrow Epidemiology
Right arrow Other hypertension
Right arrow Cardiovascular Pharmacology
Right arrow Risk Factors
Right arrowRelated Article

(Hypertension. 2006;48:213.)
© 2006 American Heart Association, Inc.


Original Articles

Long-Term and Short-Term Changes in Antihypertensive Prescribing by Office-Based Physicians in the United States

Randall S. Stafford; Veronica Monti; Curt D. Furberg; Jun Ma

From the Program on Prevention Outcomes and Practices (R.S.S., V.M., J.M.), Stanford Prevention Research Center, Stanford University, Palo Alto, Calif; and the Department of Public Health Sciences (C.D.F.), Wake Forest University School of Medicine, Winston-Salem, NC.

Correspondence to Randall S. Stafford, MD, PhD, Stanford Prevention Research Center, Stanford University, 211 Quarry Rd N161, Stanford CA 94305. E-mail rstafford{at}stanford.edu

Medication choices for the treatment of elevated blood pressure have a large potential impact on both patient outcomes and health care costs. Historic trends of prescribing for hypertension will advance the understanding of physician practice of evidence-based medicine. This study describes both long- and short-term trends in US antihypertensive prescribing from 1990 through 2004. Data were extracted from the National Disease and Therapeutic Index, a continuing survey of a national sample of US office-based physicians. Cox and Stuart and z tests were performed. Diuretics ranked among the top 3 antihypertensive drug classes throughout the entire study time span. Angiotensin-converting enzyme (ACE) inhibitors and calcium channel blockers (CCBs) were preferred over diuretics beginning in 1993, with diuretics surpassing CCBs in 2000. ß-Blockers were consistently the fourth most common class until 2002, when exceeded by angiotensin II receptor antagonists (ARBs). Most recent trends indicated an immediate but short-lived increase in the prescription of thiazide diuretics after the new clinical evidence released in December 2002 demonstrating clinical equivalence of thiazides to ACE inhibitors and CCBs. In contrast, prescription of ACE inhibitors declined, accompanied by continuation of a pre-existing increase in the prescription of ARBs, whereas prescription of CCBs remained essentially stable after the new evidence was released. The recorded long- and short-term trends indicate that evidence-based clinical recommendations had an impact on antihypertensive prescribing practices, but the magnitude of impact may be smaller and of more limited duration than desired.


Key Words: hypertension, detection and control


Related Article:

From Clinical Trials to Clinical Practice: Why the Gap?
Theodore A. Kotchen
Hypertension 2006 48: 196-197. [Full Text] [PDF]



This article has been cited by other articles:


Home page
HypertensionHome page
B. L. Carter, P. T. Einhorn, M. Brands, J. He, J. A. Cutler, P. K. Whelton, G. L. Bakris, F. L. Brancati, W. C. Cushman, S. Oparil, et al.
Thiazide-Induced Dysglycemia: Call for Research From a Working Group From the National Heart, Lung, and Blood Institute
Hypertension, July 1, 2008; 52(1): 30 - 36.
[Full Text] [PDF]


Home page
CirculationHome page
J. A. Cutler and B. R. Davis
Thiazide-Type Diuretics and {beta}-Adrenergic Blockers as First-Line Drug Treatments for Hypertension
Circulation, May 20, 2008; 117(20): 2691 - 2705.
[Full Text] [PDF]


Home page
HypertensionHome page
J. Ma and R. S. Stafford
Screening, Treatment, and Control of Hypertension in US Private Physician Offices, 2003-2004
Hypertension, May 1, 2008; 51(5): 1275 - 1281.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. Ma, K.-V. Lee, and R. S. Stafford
Response to Target Blood Pressure Level Before Antihypertensive Class to Improve Outcomes More Quickly in Uncomplicated Hypertension
Hypertension, March 1, 2007; 49(3): e17 - e17.
[Full Text] [PDF]


Home page
HypertensionHome page
K. L. Ong, B. M.Y. Cheung, Y. B. Man, C. P. Lau, and K. S.L. Lam
Prevalence, Awareness, Treatment, and Control of Hypertension Among United States Adults 1999-2004
Hypertension, January 1, 2007; 49(1): 69 - 75.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
T. A. Kotchen
From Clinical Trials to Clinical Practice: Why the Gap?
Hypertension, August 1, 2006; 48(2): 196 - 197.
[Full Text] [PDF]